About Cetrorelix
Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression
Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.
Cetrorelix Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- June 3, 1999
- Source
- View FDA source →
FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
4 sources cited · 1 strong · 3 moderate
1 Meta-analysis · 3 Cohorts
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
J Coll Physicians Surg Pak · 2026
# Summary Research found that in IVF/ICSI cycles for women with polycystic ovary syndrome, cetrorelix demonstrated the highest probability ranking for reducing ovarian hyperstimulation syndrome risk (96.9%), while leuprorelin ranked highest for improving clinical pregnancy and live birth rates. This network meta-analysis of 20 randomized controlled trials involving 2,400 patients suggested that treatment selection should be guided by individual patient priorities: cetrorelix for OHSS prevention and leuprorelin for pregnancy outcome optimization.
Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.
Eur J Pharm Sci · 2026
# Summary Research found that both oleogel and hydrogel formulations of cetrorelix acetate were successfully developed for nasal administration, with the hydrogel formulation demonstrating superior bioavailability (5.3%) and prolonged peptide absorption over 24 hours in animal studies. This study demonstrated that nasal gel delivery could represent a viable non-invasive alternative to invasive administration routes for this decapeptide therapeutic.
Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study
BMC Pregnancy and Childbirth · 2021
Research in 316 IVF-ET cycles found that half-dose cetrorelix (GnRH antagonist) yielded significantly more retrieved oocytes and available embryos than full-dose, with comparable pregnancy and live birth rates overall; among patients with BMI ≥25, half-dose was associated with higher clinical pregnancy rate, suggesting dose flexibility for patient-specific outcomes optimization.
Show 1 more source ↓
Comparison of the effects of Duphaston and Cetrotide on oocyte and embryo quality in women undergoing ICSI: a cross-sectional study
International Journal of Reproductive Biomedicine · 2020
Research in a retrospective study of 200 ICSI patients found that cetrorelix (Cetrotide) effectively prevented premature LH surge during controlled ovarian hyperstimulation, with comparable follicle counts, oocyte maturation, and viable embryo numbers to oral dydrogesterone (Duphaston), providing comparative clinical evidence for GnRH antagonist protocols in assisted reproduction.
Cetrorelix Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Cetrorelix — Providers & Availability
1 providerCoverage expanding
No verified providers currently list Cetrorelix. Get notified when one does, or explore providers carrying similar peptides in the Sexual Health category.
Stay updated on verified Cetrorelix providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Cetrorelix
Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval.
HPG axis suppression, LH/FSH reduction, controlled ovarian stimulation support, testosterone management.
Research on Cetrorelix primarily documents effects related to HPG axis suppression and LH/FSH reduction and controlled ovarian stimulation support and testosterone management. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Cetrorelix include hormone-sensitive cancers (with caution), pregnancy, renal impairment. This is educational information only — consult a qualified healthcare professional before use.
1 provider in the directory currently offers Cetrorelix.
# Summary Research found that in IVF/ICSI cycles for women with polycystic ovary syndrome, cetrorelix demonstrated the highest probability ranking for reducing ovarian hyperstimulation syndrome risk (96.9%), while leuprorelin ranked highest for improving clinical pregnancy and live birth rates. This network meta-analysis of 20 randomized controlled trials involving 2,400 patients suggested that treatment selection should be guided by individual patient priorities: cetrorelix for OHSS prevention and leuprorelin for pregnancy outcome optimization.